CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 55 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00304161
NCT00304161Phase 4Completed
CompareCT.gov

Depression Diagnosis and Treatment in Parkinson Disease

University of Pennsylvania·interventional·Posted Mar 17, 2006·Updated Jan 30, 2017

In Brief

A Phase 4 clinical trial evaluating Atomoxetine and Placebo for Depressive Disorder and Parkinson Disease. Completed, enrolled 55 participants across 2 sites.

Detailed Summary

This study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression in people with Parkinson's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Parkinson Disease
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 17, 2006
Enrollment StartJul 1, 2004
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 20.3 years ago

Interventions

Atomoxetinedrug

40 to 80 mg orally once daily for 8 weeks

Placebodrug

40 to 80 mg orally once daily for 8 weeks